Corpus Intelligence IC Memo — ST. PETERS UNIVERSITY HOSPITAL 2026-04-26 04:05 UTC
IC Memo — ST. PETERS UNIVERSITY HOSPITAL
Investment Committee Memorandum | NJ | 352 beds | Grade C | EBITDA uplift $40.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ST. PETERS UNIVERSITY HOSPITAL

CCN 310070 | MIDDLESEX, NJ | 352 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ST. PETERS UNIVERSITY HOSPITAL is a 352-bed suburban community hospital in MIDDLESEX, NJ with $543.0M in net patient revenue and a 1.9% operating margin. The hospital serves a payer mix of 17.2% Medicare, 8.1% Medicaid, and 74.7% commercial.

Thesis: Undervalued. Our ML models identify $40.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 1.9% to 9.3% (+736bps).

Net Revenue HCRIS$543.0M
Current EBITDA COMPUTED$10.5M
Operating Margin COMPUTED1.9%
Occupancy HCRIS70.2%
Revenue / Bed COMPUTED$1.5M
Net-to-Gross HCRIS14.8%
Distress Probability ML42.7%

2. Market Context & Competitive Position

95
NJ Hospitals
-3.9%
State Median Margin
44
Comparable Hospitals

NJ has 95 Medicare-certified hospitals with a median operating margin of -3.9%. The target's margin of 1.9% places it above the state median. Among 44 size-comparable peers (176-704 beds), the median margin is -3.9%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (176-704), prioritizing same-state peers. 44 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ST. PETERS UNIVERSITY HOSPITAL (Target)NJ352$543.0M1.9%
COOPER UNIVERSITY HOSPITALNJ580$1.43B2.0%
ROBERT WOOD JOHNSON UNIVERSITYNJ639$1.41B-4.0%
JERSEY SHORE UNIVERSITY MED CTNJ604$1.17B8.4%
COOPERMAN BARNABAS MEDICAL CENNJ554$1.07B-4.3%
ENGLEWOOD HOSPITAL & MED CTRNJ292$967.3M0.1%
WEST JERSEY HEALTH SYSTEMNJ587$958.4M7.1%
THE VALLEY HOSPITALNJ385$951.8M17.5%
OVERLOOK MEDICAL CENTERNJ440$880.2M8.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $40.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$11.4M+210bp18mo
Cost to Collect4.5%2.5%$10.9M+200bp12mo
Denial Rate Reduction12.0%6.5%$10.8M+198bp12mo
A/R Days Reduction5200.0%3800.0%$6.6M+122bp9mo
Clean Claim Rate88.0%96.0%$348K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$11.4M
Cost to Collect
$10.9M
Denial Rate Reduction
$10.8M
A/R Days Reduction
$6.6M
Clean Claim Rate
$348K
Total EBITDA Uplift$40.0M
Current EBITDA$10.5M
+ RCM Uplift+$40.0M
Pro Forma EBITDA$50.5M
Current Margin1.9%
Pro Forma Margin9.3%
WC Released (1x)$20.8M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$16.2M$469.1M28.97x96.1%
Base (11x exit)10.0x11.0x$16.2M$521.3M32.20x100.2%
Bull Case9.0x11.0x$14.6M$658.4M45.19x114.3%
Bull (12x exit)9.0x12.0x$14.6M$722.6M49.59x118.3%
Bear Case11.0x10.0x$17.8M$264.0M14.82x71.5%
Bear (11x exit)11.0x11.0x$17.8M$296.2M16.63x75.5%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 44 hospitals with 176-704 beds
  • Same-state prioritization (n=45)
  • Comp margins: P25=-12.5% / P50=-3.9% / P75=2.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.